Prevention Studies
AZD0780 - D7960C00015: This phase III study assesses the effect of AZD0780 compared with placebo in reducing the risk of major adverse cardiovascular events (MACE-PLUS) in participants with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for a first ASCVD event.
More information
AZD0780 - D7960C00012: The purpose of this phase III study is to evaluate the efficacy, safety, and tolerability of AZD0780 in patients with elevated LDL-C and clinical atherosclerotic cardiovascular disease (ASCVD) or at risk for a first ASCVD event.
More information
DAL-GENE-2: This study evaluates the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal heart attacks in patients with a documented recent acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene.
More information
Heart Failure Studies
CORCINCH-HF: This clinical study evaluates the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
More information
EMPOWER: This clinical trial assesses the safety and efficacy of the Carillon Mitral Contour System in treating heart failure patients who have early-stage functional mitral regurgitation (FMR).
More information
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III: This study evaluates the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III heart failure patients (PROACTIVE-HF-2 Trial).
More information
Device Studies
AMPLATZER PFO: This study confirms the safety and effectiveness of the AMPLATZER PFO Occluder in the post-approval setting.
More information
CATALYST: This clinical trial evaluates the safety and effectiveness of the Amulet device compared to novel oral anticoagulant (NOAC) therapy in patients with non-valvular atrial fibrillation at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy.
More information
COMPLETE TAVR: Among patients who have undergone a successful elective transfemoral TAVR, this study will determine whether a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new heart attack, ischemia driven revascularization or hospitalization.
More information
CONFORM: This study evaluates if the CLAAS® device is similar in safety and efficacy to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation.
More information
EDWARDS PASCAL CLASP IID/IIF Pivotal Clinical Trial: This study evaluates the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with mitral regurgitation.
More information
ENCIRCLE: This study will establish the safety and effectiveness of the SAPIEN M3 System in people with symptomatic, at least 3+ mitral regurgitation (MR), for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.
More information
EPX-HTG-2025: This study reviews the safety and efficacy of EchoPixel Holographic Therapy Guidance (HTG) Procedural WATCHMAN FLX with TRUSTEER implantation.
PREVAIL GLOBAL: The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail drug-coated balloon.
More information
PROGRESS CAP: This study’s objective is to establish the safety and effectiveness of the Edwards SAPIEN 3/ SAPIEN 3 Ultra Transcatheter Heart Valve in subjects with moderate, calcific aortic stenosis.
More information
QUADRA-PE: This study examines the safety and effectiveness of the Akura Thrombectomy System for use in the removal of emboli from the pulmonary arteries in treating acute pulmonary embolism (PE).
More information
SIMPLAAFY: The primary objective of this study is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
More information
SPYRAL AFFIRM: This study seeks to determine the long-term safety, efficacy and durability of the Symplicity Spyral system in subjects treated with renal denervation. Watch a Simplicity Spyral Procedure Animation.
More Information
MyChart